Inproteo
351 West 10th, Suite 120
Indianapolis, Indiana 46202
317.278.8185
FAX 317.278.8190
info@proteo.com
 |
Inproteo351 West 10th, Suite 120 |
|
A new corporation successfully applying analytical chemistry to design, create and optimize novel instrumentation and methodologies that will generate actionable information for the discovery and development of diagnostic and therapeutic agents.
Peter T. Kissinger, Ph.D.
President
pete@bioanalytical.com
Anthony J. Hubbard
Chief Financial Officer
ajhubbar@iupui.edu
Cynthia J. Helphingstine
Vice President
cjhelphi@iupui.edu
Discussions began early in 2001 to create a mechanism for scientists from Purdue University, Indiana University, and Eli Lilly and Company to work together on projects that would leverage the two universities' world-class experience in analytical chemistry and instrumentation, and Lilly's long history of experience with protein therapeutics and protein drug targets. The goal was to go beyond traditional academic/industry partnerships to create a unique synergistic environment for breakthrough innovation that would far exceed the value of any singly sponsored project involving only one or two of the institutions. A secondary goal was to bring recognition to Indiana as an attractive region for investment in the life sciences. Four exciting and revolutionary projects were selected to initiate the Consortium, and the newly formed company initiated operations early in April 2002. As an entity the consortium provides a focused research environment of communication, knowledge sharing and biomedical application.
Proteomics has the potential to improve radically our understanding of disease and wellness. The Consortium is working to unleash that potential to improve human health by applying analytical chemistry to design, create and optimize novel instrumentation and methodologies that will generate actionable information for the discovery and development of diagnostic and therapeutic agents. The Consortium's collaborative and synergistic cross-institutional projects will result in new technologies that can be licensed or spun off into new companies.